Position in JNJ
as of Jun 30, 2026
· filed Jul 9, 2026
Position Value
$456,892
+$36,456 QoQ
Shares Held
1,799
+4.6% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.91%
of 13F equity value
Holder Rank
#3,787
of 4,664 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in JNJ Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Ares Financial Consulting, LLC holds $2,336,042 across 14 Drug Manufacturers - General names. JNJ ranks #2 (19.6% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | PFE |
Pfizer Inc
|
22,342 | $537,995 | |
| 2 | JNJ |
Johnson & Johnson
This page
|
1,799 | $456,892 | |
| 3 | LLY |
ELI LILLY & Co
|
379 | $454,584 | |
| 4 | ABBV |
AbbVie Inc.
|
980 | $246,607 | |
| 5 | MRK |
Merck & Co., Inc.
|
1,030 | $132,355 | |
| 6 | AMGN |
Amgen Inc
|
310 | $112,257 | |
| 7 | AZN |
Astrazeneca PLC
|
486 | $92,155 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
596 | $75,298 |
All Filings in JNJ
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $456,892 | 1,799 | Shares | Sole | 2026-07-09 | |
| 2026-03-31 | $420,436 | 1,720 | Shares | Sole | 2026-04-02 | |
| 2025-12-31 | $281,245 | 1,359 | Shares | Sole | 2026-01-30 | |
| No filing history on record for this holder in this stock. | ||||||